VEGFB and macular retinal edema: As a fusion protein, aflibercept, specifically binding VEGF-A, VEGF-B, and PlGF, inhibits the downstream signaling of VEGFR1/2, thereby reducing BRB breakdown and angiogenesis and reducing macular edema and retinal neovascularization.